Celgosivir
Based on 3 publication(s) in Google Scholar
Celgosivir (MBI 3253; MDL 28574; MX3253) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in in vitro assay.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.02%
- CAS. Nr.: 121104-96-9
- Formel: C12H21NO5
- Molecular Weight:259.30
-
Speicherung:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-16134A
Celgosivir hydrochlorideα-Glucosidase I Inhibitor -
HY-10238
DanoprevirHCV NS3/4A Inhibitor -
HY-100944
Conduritol B epoxideGcase Inhibitor -
HY-125033
EIDD-1931Anti-Virus Agent -
HY-10468
NM107HCV NS5B Polymerase Inhibitor -
HY-10237
BoceprevirHCV NS3 Protease Inhibitor -
HY-N2025
Oroxin APartial PPARγ Agonist -
HY-10238R
Danoprevir (Standard)Reference Standard -
HY-15298A
Grazoprevir potassium saltHCV Inhibitor -
HY-107532
N-NonyldeoxynojirimycinGlucosidase Inhibitor -
HY-N7626
EleutherolAntifungal Agent -
HY-10235
TelaprevirHCV NS3-4A Protease Inhibitor
Publications Citing Use of MedChemExpress (MCE) Celgosivir
More
Biologische Aktivität
Beschreibung
IC50 & Target
|
HIV-1 |
In Vitro
Celgosivir is more effective (IC50=20 μM) than the parent molecule (IC50=254 μM) at causing the accumulation of glucosylated oligosaccharides in HIV-infected cells by inhibition of glycoprotein processing. Celgosivir exhibits potent antiviral activity against HIV-1 with an IC50 of 2.0±2.3 μM[1]. Bovine viral diarrhoea virus (BVDV) is a closely related virus of hepatitis C virus (HCV). Celgosivir inhibits BVDV with IC50 values of 16 and 47 μM in plaque assay and cytopathic effect assay, respectively[2]. Celgosivir inhibits DENV2 replication with an EC50 of 0.2 μM. The EC50 values against DENV1, 3 and 4 are less than 0.7 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 121104-96-9
-
Appearance Solid
-
Molecular Weight 259.30
-
Formel C12H21NO5
-
Color White to off-white
-
SMILES
O[C@@H]1[C@]2([H])[C@@H](O)[C@H](O)[C@@H](OC(CCC)=O)CN2CC1
-
Synonyms
MBI 3253; MDL 28574; MX3253
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
-
J Virol
STT3B promotes porcine epidemic diarrhea virus replication by regulating N-glycosylation of PEDV S protein. [Abstract]2025 Mar 18;99(3):e0001825. PMID: 39945486 -
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Taylor DL, et al. Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoylcastanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrob Agents Chemother. 1994 Aug;38(8):1780-7. [Content Brief]
[2]. Rathore AP, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes andprotects against lethal challenge mouse model. Antiviral Res. 2011 Dec;92(3):453-60. [Content Brief]
[3]. Whitby K, et al. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antivir Chem Chemother. 2004 May;15(3):141-51. [Content Brief]
[4]. Watanabe S, et al. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 2012 Oct;96(1):32-5. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Celgosivir Related Classifications
HY-16134 Related Classifications
Powered by Bioz